Cancer-associated O-glycans and microbiome interactions in colorectal cancer: insights into tumor progression and immune evasion

Abstract

Glycans play a crucial role in modulating cellular interactions and disease progression. In the colon, they serve as key mediators between host cells, the microbiome, and the immune system. During tumorigenesis, however, glycans undergo significant alterations that not only influence oncogenic pathways but are also affected by changes in cell signaling, creating a self-perpetuating cycle. These feedback loops drive several cancer hallmarks, including sustained proliferative signaling and immune escape, thereby promoting disease progression. One prominent alteration in colorectal cancer is increased sialylation - the enrichment of sialic acid-containing glycans - which is strongly linked to tumor development, progression, and poor prognosis. Truncated O-glycan structures, such as the Sialyl-Tn (STn) antigen, are rarely presented in healthy colon tissue but are commonly associated with oncogenic transformation and immune evasion. Both commensal and pathogenic bacteria in the colon exploit host sialylated glycans as adhesion sites and nutrient sources. This interaction modulates local immune responses and inflammation, contributing to a complex and dynamic interplay that, when disrupted, accelerates cancer progression. This mini-review discusses the role of sialylated cancer-associated glycans in colorectal cancer, emphasising their involvement in tumor progression, metastasis, and interactions with the gut microbiome. Furthermore, it highlights emerging therapeutic strategies that target these glycans.

Keywords

Glycans / gastrointestinal / colorectal tumorigenesis / microbiome / immune evasion

References

[1] Varki A.Nothing in glycobiology makes sense, except in the light of evolution.Cell2006;126:841-5

[2] Määttänen P,Bergeron JJ.Protein quality control in the ER: the recognition of misfolded proteins.Semin Cell Dev Biol2010;21:500-11

[3] Reily C,Renfrow MB.Glycosylation in health and disease.Nat Rev Nephrol2019;15:346-66 PMCID:PMC6590709

[4] Xu Y,Wagner GK.Chapter Nine - Covalent probes for carbohydrate-active enzymes: from glycosidases to glycosyltransferases.Methods Enzymol2018;598:237-65

[5] Brockhausen I,Hagen Ten KG.O-GalNAc Glycans. 2022.

[6] Stanley P.N-Glycans. Encyclopedia of cell biology. Elsevier; 2023. pp. 487-94.

[7] Bangarh R,Kaur S.Aberrant protein glycosylation: implications on diagnosis and Immunotherapy.Biotechnol Adv2023;66:108149

[8] Purushothaman A,Lele TP.The role of glycans in the mechanobiology of cancer.J Biol Chem2023;299:102935 PMCID:PMC9930169

[9] La Rosa SL,Vera-Ponce de León A.Glycan processing in gut microbiomes.Curr Opin Microbiol2022;67:102143

[10] Verhelst X,Colombel JF.Protein glycosylation as a diagnostic and prognostic marker of chronic inflammatory gastrointestinal and liver diseases.Gastroenterology2020;158:95-110

[11] Silva MC,Oliveira M.Glycans as immune checkpoints: removal of branched N-glycans enhances immune recognition preventing cancer progression.Cancer Immunol Res2020;8:1407-25

[12] Xu X,Jiang X.Altered glycosylation in cancer: molecular functions and therapeutic potential.Cancer Commun2024;44:1316-36 PMCID:PMC11570773

[13] Fernandes A,Silva MC.Glycans as shapers of tumour microenvironment: a sweet driver of T-cell-mediated anti-tumour immune response.Immunology2023;168:217-32

[14] Crocker PR.Properties and distribution of a lectin-like hemagglutinin differentially expressed by murine stromal tissue macrophages.J Exp Med1986;164:1862-5 PMCID:PMC2188478

[15] Angata T,Nakamura K.Siglec-15: an immune system Siglec conserved throughout vertebrate evolution.Glycobiology2007;17:838-6

[16] Lehmann F,Kelm S.Evolution of sialic acid-binding proteins: Molecular cloning and expression of fish siglec-4.Glycobiology2004;14:959-8

[17] Angata T,Green ED.Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms.Proc Natl Acad Sci USA2004;101:13251-6 PMCID:PMC516556

[18] Duan S.Siglecs as immune cell checkpoints in disease.Annu Rev Immunol2020;38:365-95

[19] Pillai S,Cariappa A.Siglecs and immune regulation.Annu Rev Immunol2012;30:357-92 PMCID:PMC3781015

[20] Crocker PR,Varki A.Siglecs and their roles in the immune system.Nat Rev Immunol2007;7:255-66

[21] Macauley MS,Paulson JC.Siglec-mediated regulation of immune cell function in disease.Nat Rev Immunol2014;14:653-66 PMCID:PMC4191907

[22] Hudak JE,Bertozzi CR.Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion.Nat Chem Biol2014;10:69-75 PMCID:PMC3893890

[23] Santegoets KCM,Büll C.Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.Cancer Immunol Immunother2019;68:937-49 PMCID:PMC6529385

[24] Silva Z,Luz V.New insights into the immunomodulatory potential of sialic acid on monocyte-derived dendritic cells.Cancer Immunol Immunother2024;74:9 PMCID:PMC11531459

[25] Silva Z,Barbosa M,Marcelo F.The role of sialoglycans in modulating dendritic cell function and tumour immunity.Semin Immunol2024;74-5:101900

[26] Edwards DL,Wang TT.Soluble factors and mechanisms regulated by sialylated IgG signaling.Immunol Rev2025;330:e70021 PMCID:PMC12042769

[27] Dall'Olio F,Trinchera M.Sialosignaling: sialyltransferases as engines of self-fueling loops in cancer progression.Biochim Biophys Acta2014;1840:2752-64

[28] Harduin-lepers. Comprehensive analysis of sialyltransferases in vertebrate genomes.Glycobiol Insights2010;2:29-61

[29] Picco G,Brockhausen I.Over-expression of ST3Gal-I promotes mammary tumorigenesis.Glycobiology2010;20:1241-50 PMCID:PMC2934706

[30] Kvorjak M,Miller ML.Cross-talk between colon cells and macrophages increases ST6GALNAC1 and MUC1-sTn expression in ulcerative colitis and colitis-associated colon cancer.Cancer Immunol Res2020;8:167-78

[31] Ferreira JA,Lima L.Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours.Mol Oncol2013;7:719-31 PMCID:PMC5528473

[32] Carrascal MA,Guadalupe Cabral M.Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells.Mol Oncol2014;8:753-65 PMCID:PMC5528624

[33] Jiang Y,Xu F.Aberrant O-glycosylation contributes to tumorigenesis in human colorectal cancer.J Cell Mol Med2018;22:4875-85 PMCID:PMC6156240

[34] Zeng J,Wang Y.Promoters of human cosmc and T-synthase genes are similar in structure, yet different in epigenetic regulation.J Biol Chem2015;290:19018-33

[35] Sun X,Cummings RD.Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers.BMC Cancer2018;18:1-15 PMCID:PMC6097208

[36] Gao T,Hu X.Cosmc overexpression enhances malignancies in human colon cancer.J Cell Mol Med2020;24:362-70 PMCID:PMC6933370

[37] Futamura N,Tatematsu M,Kannagi R.Clinicopathologic significance of sialyl Le ^xexpression in advanced gastric carcinoma.Br J Cancer2000;83:1681-7 PMCID:PMC2363447

[38] Shen L,Wu J.Enhanced expression of α2,3-linked sialic acids promotes gastric cancer cell metastasis and correlates with poor prognosis.Int J Oncol2017;50:1201-10

[39] Zhou X,Zhang C,Yang G.Sialylation: a cloak for tumors to trick the immune system in the microenvironment.Biology2023;12:832 PMCID:PMC10294807

[40] Venkitachalam S,Varadan V.Biochemical and functional characterization of glycosylation-associated mutational landscapes in colon cancer.Sci Rep2016;6:23642

[41] Wang D,Madunić K.In-depth analysis of the N-glycome of colorectal cancer cell lines.Int J Mol Sci2023;24:4842 PMCID:PMC10003090

[42] Rodrigues JG,Gomes C.Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells.Cell Oncol2021;44:835-50

[43] Mereiter S,Gomes J,Reis CA.Glycomic approaches for the discovery of targets in gastrointestinal cancer.Front Oncol2016;6:55 PMCID:PMC4783390

[44] Deschepper FM,Pirro M.L1CAM as an E-selectin ligand in colon cancer.Int J Mol Sci2020;21:8286 PMCID:PMC7672641

[45] Wang D,Mayboroda OA,Wuhrer M.(Sialyl)Lewis antigen expression on glycosphingolipids, N-, and O-glycans in colorectal cancer cell lines is linked to a colon-like differentiation program.Mol Cell Proteomics2024;23:100776 PMCID:PMC11128521

[46] Gomes C,Pinto MT,Oliveira MJ.Expression of ST3GAL4 leads to SLe ^xexpression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells.PLoS One2013;8:e66737 PMCID:PMC3682978

[47] Tian H,Chu X,Liu J.Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression.Front Oncol2024;14:1389713 PMCID:PMC11063370

[48] Vázquez-Martín C,Gil-Martín E.Correlation analysis between tumor-associated antigen sialyl-Tn expression and ST6GalNAc I activity in human colon adenocarcinoma.Oncology2004;67:159-65

[49] Dombek GE,Cheng J.Immunohistochemical analysis of Tn antigen expression in colorectal adenocarcinoma and precursor lesions.BMC Cancer2022;22:1281 PMCID:PMC9730631

[50] Yao Y,Shafer S.Mucus sialylation determines intestinal host-commensal homeostasis.Cell2022;185:1172-88.e28

[51] Lee S,Lee GY,Mahato SK.Glycan-mediated molecular interactions in bacterial pathogenesis.Trends Microbiol2022;30:254-67 PMCID:PMC8758796

[52] Kotlarz D.Mucus sialylation maintains the peace in intestinal host microbe relations.Gastroenterology2022;163:527-8

[53] Taniguchi M,Matsuzaki T.Sialylation shapes mucus architecture inhibiting bacterial invasion in the colon.Mucosal Immunol2023;16:624-41

[54] Dedola S,de Andrade P.Sialic acids in infection and their potential use in detection and protection against pathogens.RSC Chem Biol2024;5:167-88 PMCID:PMC10915975

[55] Arai J,Tateno H,Kasuga M.The role of gastric mucins and mucin-related glycans in gastric cancers.Cancer Sci2024;115:2853-61 PMCID:PMC11463072

[56] Leite-Gomes E,Azevedo CM.Bringing to light the risk of colorectal cancer in inflammatory bowel disease: mucosal glycosylation as a key player.Inflamm Bowel Dis2022;28:947-62

[57] Okumura R.The role of the mucosal barrier system in maintaining gut symbiosis to prevent intestinal inflammation.Semin Immunopathol2024;47:2 PMCID:PMC11599372

[58] Pothuraju R,Krishn SR.Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance.Mol Cancer2020;19:37 PMCID:PMC7041280

[59] Rebersek M.Gut microbiome and its role in colorectal cancer.BMC Cancer2021;21:1325 PMCID:PMC8666072

[60] Ma X,Wang X,Wei L.Sialylation in the gut: from mucosal protection to disease pathogenesis.Carbohydr Polym2024;343:122471

[61] Wong SH.Gut microbiota in colorectal cancer: mechanisms of action and clinical applications.Nat Rev Gastroenterol Hepatol2019;16:690-704

[62] Casasanta MA,Udayasuryan B.Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration.Sci Signal2020;13:eaba9157 PMCID:PMC7454160

[63] Duizer C,van Gogh M.Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1.Gut Microbes2025;17:2458203 PMCID:PMC11784648

[64] Abed J,Zamir G.Fap2 mediates fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc.Cell Host Microbe2016;20:215-25 PMCID:PMC5465824

[65] Caldevilla R,Santos DAR.Advancing non-invasive colorectal cancer screening: exploring the potential of monoclonal antibody L2A5.Int J Mol Sci2025;26:3070 PMCID:PMC11988763

[66] Neves M,Lima L.Exploring sialyl-Tn expression in microfluidic-isolated circulating tumour cells: a novel biomarker and an analytical tool for precision oncology applications.N Biotechnol2019;49:77-87

[67] Houvast RD,Durrant LG.Targeting glycans and heavily glycosylated proteins for tumor imaging.Cancers2020;12:3870 PMCID:PMC7767531

[68] Ibrahim NK.Clinical development of the STn-KLH vaccine (Theratope).Clin Breast Cancer2003;3 Suppl 4:S139-43

[69] Holmberg LA.Vaccination with Theratope® (STn-KLH) as treatment for breast cancer.Expert Rev Vaccines2004;3:655-63

[70] Sterner E,Gildersleeve JC.Perspectives on anti-glycan antibodies gleaned from development of a community resource database.ACS Chem Biol2016;11:1773-83 PMCID:PMC4949583

[71] Loureiro LR,Bergmann R.Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers.J Exper Clin Cancer Res2020;39:77 PMCID:PMC7201957

[72] Loureiro LR,Bergmann R.Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells.Blood Cancer J2018;8:81

[73] Al-Alem L,Clark J.Sialyl-Tn serves as a potential therapeutic target for ovarian cancer.J Ovarian Res2024;17:71 PMCID:PMC10985924

[74] Manni M.Targeting glyco-immune checkpoints for cancer therapy.Expert Opin Biol Ther2021;21:1063-71

[75] Videira PA,Grewal RK.Glycosyltransferase inhibitors: a promising strategy to pave a path from laboratory to therapy.Carbohydr Chem2017;43:135-58

[76] Sánchez-Martínez E,Moreno FJ.Functional role of ST6GALNAC1-mediated sialylation of mucins in preserving intestinal barrier integrity and ameliorating inflammation.Allergy2022;77:3697-8